This webinar will discuss the FDA requirements and guidelines for investigating Out-of-trend (OOT) results in the pharmaceutical laboratory. It will also cover FDA-compliant documentation of OOT, failure investigations, root causes, and CAPA.
WHY SHOULD YOU ATTEND?
FDA's guidance on OOS test results requires failure investigations and other steps for Out-of-Specification (OOS) and Out-of-trend (OOT) results. While most companies are familiar with and have procedures for OOS results, this is not the case for OOT situations. The guide states: "Although the subject of this document is OOS results, much of the guidance may be useful for examining results that are out of trend". Managing OOT results also helps to avoid time-consuming OOS results. The industry is unsure how to interpret and implement the FDA guidance.
This session will equip you with the knowledge and comprehensive understanding of FDA requirements for Out-of-Trend Results in pharmaceutical quality control.
AREA COVERED
- FDA regulations and guidelines.
- FDA's final Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.
- Difference between OOS and OOT results.
- Developing SOPs for OOT situations and laboratory failures.
- Investigating OOT results: what and how.
- Retesting of OOT results.
- Using historical data for OOT evaluation.
- Using QC samples and product control charts for evaluation.
- Developing corrective and preventive action plans.
- Finding the root cause for OOT results.
- Strategies to avoid OOS situations BEFORE they occur.
- FDA-compliant documentation of OOS, OOT, failure investigations, root causes, and CAPA.
WHO WILL BENEFIT?
- Lab Supervisors and Managers
- QA managers and personnel
- Pharmaceutical R&D personnel
- Documentation
- Consultants
- Contract laboratories
- CROs
FDA's guidance on OOS test results requires failure investigations and other steps for Out-of-Specification (OOS) and Out-of-trend (OOT) results. While most companies are familiar with and have procedures for OOS results, this is not the case for OOT situations. The guide states: "Although the subject of this document is OOS results, much of the guidance may be useful for examining results that are out of trend". Managing OOT results also helps to avoid time-consuming OOS results. The industry is unsure how to interpret and implement the FDA guidance.
This session will equip you with the knowledge and comprehensive understanding of FDA requirements for Out-of-Trend Results in pharmaceutical quality control.
- FDA regulations and guidelines.
- FDA's final Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.
- Difference between OOS and OOT results.
- Developing SOPs for OOT situations and laboratory failures.
- Investigating OOT results: what and how.
- Retesting of OOT results.
- Using historical data for OOT evaluation.
- Using QC samples and product control charts for evaluation.
- Developing corrective and preventive action plans.
- Finding the root cause for OOT results.
- Strategies to avoid OOS situations BEFORE they occur.
- FDA-compliant documentation of OOS, OOT, failure investigations, root causes, and CAPA.
- Lab Supervisors and Managers
- QA managers and personnel
- Pharmaceutical R&D personnel
- Documentation
- Consultants
- Contract laboratories
- CROs
Speaker Profile

Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.
Upcoming Webinars

Managing Toxic Employees: Strategies For Leaders To Effecti…

Marketing to Medicare or Medicaid Beneficiaries - What You …

Effective Onboarding: How to Welcome, Engage, and Retain Ne…




Employee Engagement, Empowerment and Motivation in Challeng…

2023 EEOC and Employers: Investigating Harassment and Discr…

Being Seen as a Human Resource Strategic Business Partner

Managing International Employee Payroll & Tax Services


Six Thinking Hats - Structuring Creative Thinking (Paralle…

Delivering Constructive Criticism - Best Practices

How to Effectively Conduct Annual Employee Reviews

3-Hour Excel Automation Boot Camp: Top Ten Excel Functions …

Self Esteem Matters: An Ethics Based Webinar for Women

Accounting For Non Accountants : Debit, Credits And Financi…


New Ideas and Tools for Effective Performance Management 20…


Supervising a Human Error Free Environment: You can do a Lo…

Effectively Handling CP 2100 letter and B Notices

Basic Accounting and Finance for the Human Resources Profes…

Compliance with Stop Payments vs Unauthorized Transactions

Finally! The New I-9 Form and The Extension of the DHS Remo…

The Most Frequent 483's for Medical Device Companies in 2022

CAPA/Root Cause Analysis: Achieving Compliance with Proper …

Secrets Of Psychology - Why People Do The Things They Do

Remaining Agile in an Ever-Changing Climate

Project Management for administrative professionals

4-Hour Virtual Seminar on FMLA BOOTCAMP: Managing Complianc…


Succession Planning for Sustainable Small and Family Busine…